
Renshan Health International Pharmaceutical Private Limited
Founded in 2018 and headquartered in Delhi, India.
Founded in 2018 and headquartered in Delhi, India.
New Delhi, India
+91-XXXXXXXXXX
U85100DL2018FTC341571
341571
Private Limited Foreign Company Incorporated In India
05 Nov 2018
-
-
Unlisted
Roc Delhi
Name | Designation | Appointment Date | Status |
---|---|---|---|
Jitesh Agarwal ![]() | Director | 05-Nov-2018 | Current |
Garima Mitra ![]() | Director | 05-Nov-2018 | Current |
Enhance accessibility to Renshan Health International Pharmaceutical's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue | |||||||
Revenue from Operations | |||||||
Total Assets | |||||||
Profit or Loss | |||||||
Net Worth | |||||||
EBITDA |
Unlock access to Renshan Health International Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Garima Mitra and Jitesh Agarwal are mutual person
Garima Mitra and Jitesh Agarwal are mutual person
Jitesh Agarwal is a mutual person
Garima Mitra and Jitesh Agarwal are mutual person
Jitesh Agarwal is a mutual person
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Renshan Health International Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Renshan Health International Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Renshan Health International Pharmaceutical's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Garima Bhupendra Mitra was appointed as a Director was appointed as a Director on 05 Nov 2018 & has been associated with this company since 6 years 4 months .
Jitesh Pradeep Agarwal was appointed as a Director was appointed as a Director on 05 Nov 2018 & has been associated with this company since 6 years 4 months .
Renshan Health International Pharmaceutical Private Limited was registered on 05 Nov 2018 with Roc Delhi & aged 6 years 4 months as per MCA records.
Renshan Health International Pharmaceutical Private Limited was incorporated on 05 Nov 2018.
The authorized share capital of Renshan Health International Pharmaceutical Private Limited is ₹ 1.00 M and paid-up capital is ₹ 0.50 M.
Currently 2 directors are associated with Renshan Health International Pharmaceutical Private Limited.
As per Ministry of Corporate Affairs (Mca), the registered address of Renshan Health International Pharmaceutical Private Limited is 602 A-Block Naurang Bhawan, K. G Marg India, New Delhi, 110001.
The corporate identification number (CIN) of Renshan Health International Pharmaceutical Private Limited is U85100DL2018FTC341571 and the company number is 341571 as per Ministry of Corporate Affairs (MCA).